Mimedx (MDXG) Price to Sales (2011 - 2026)

Mimedx has disclosed Price to Sales across 16 years of filings, most recently posting 8.72 for Q2 2026.

• In Q2 2026, Price to Sales fell 4.9% year-over-year to 8.72; the TTM figure through Jun 2026 stood at 1.58 (down 36.42% YoY), while the FY2025 annual figure was 2.39, down 40.89% from the prior year.
• Price to Sales came in at 8.72 for Q2 2026 at Mimedx, down from 9.97 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 15.21 in Q4 2024 to a low of 4.25 in Q4 2022.
• Average Price to Sales over 5 years is 9.44, with a median of 9.31 recorded in 2023.
• Year-over-year, Price to Sales plunged 71.29% in 2022 and soared 176.84% in 2023.
• Over 5 years, Price to Sales stood at 4.25 in 2022, then soared by 176.84% to 11.77 in 2023, then increased by 29.3% to 15.21 in 2024, then sank by 44.2% to 8.49 in 2025, then advanced by 2.68% to 8.72 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 8.72 in Q2 2026, 9.97 in Q1 2026, and 8.49 in Q4 2025.